Vero Biotech

Executive Summary

Vero Biotech is a private biotechnology company based in Atlanta, Georgia, specializing in the design and commercialization of next-generation inhaled nitric oxide (iNO) delivery systems for acute cardiopulmonary conditions. Its flagship product, the GENOSYL® Delivery System (DS), is a tankless iNO platform that simplifies administration, reduces waste, and improves patient outcomes compared to traditional cylinder-based systems. The company's mission is to enhance care in acute settings through innovative technology and superior customer service. Since its founding in 2016, Vero Biotech has focused on addressing unmet needs in pulmonary hypertension and hypoxic respiratory failure, positioning itself as a leader in the iNO delivery market. Looking ahead, Vero Biotech is poised to expand its market presence through potential regulatory approvals and strategic partnerships. The company may seek FDA clearance for expanded indications, such as pediatric use or longer treatment durations, which could significantly broaden its addressable patient population. Additionally, collaborations with major hospital networks or group purchasing organizations could accelerate adoption of the GENOSYL DS. With a strong product profile and a growing focus on cost-effective acute care solutions, Vero Biotech is well-positioned for sustained growth in the coming years.

Upcoming Catalysts (preview)

• Q4 2026FDA approval for expanded pediatric indication65% success
• Q3 2026Strategic partnership with a major hospital network for GENOSYL DS adoption75% success
• Q2 2026Positive top-line results from a Phase 2 trial in COPD patients50% success